Marker for predicting the sensitivity to PI3K inhibitors

US12000833B2 · kind B2 · utility

Assignees

• INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
• UNIVERSITE PAUL SABATIER—TOULOUSE III · FR
• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR

Inventors

• Julie Guillermet-Guibert · Toulouse, FR
• Thibaut Douche · Toulouse, FR
• Emmanuelle Mouton-Barbosa · Toulouse, FR
• Odile SCHILTZ · Toulouse, FR
• Marie-Pierre Bousquet · Bourg-la-Reine, FR
• Celia Cintas · Nairobi, KE

Key dates

• Filing date: Nov 22, 2018
• Grant date: Jun 4, 2024
• Expiry date: Jan 7, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K7/08
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

PI3K signalling is the most increased pathway in human cancers. The four isoforms of PI3K are thought to be activated by different redundant mechanisms leading to a common downstream signalling. However, the mutational pattern of PI3K pathway or its level of expression is not sufficient to predict the sensitivity to PI3K inhibitors. By identifying for the first time a phosphopeptide that predict the sensitivity to p110α and/or p110γ inhibitors, the inventors provide insight in how to handle heterogeneity of PI3K expression patterns in tumoral samples for the choice of available PI3K-targetting drugs. Accordingly, the present relates to a phosphopeptide characterized by the amino acid sequence as set forth in SEQ ID NO:1 (PGTPSDHQSQEASQFER) wherein the threonine residue at position 3 is phosphorylated.